title: Effect of pravastatin on cisplatin-induced nephrotoxicity in rats.
abstract: We investigated whether pravastatin ameliorates renal damage induced by cisplatin (CP). Forty-three male Wistar rats were divided into four groups: rats treated with a control diet for 19 days and saline injection on day 14 (group1), group 1 with pravastatin treatment with 19 days (group 2), group 1 with CP injection on day 14 (group 3), and group 2 with CP injection (group 4). Renal function and serum lipids, renal malondialdehyde (MDA) and glutathione (GSH) levels, glutathione peroxidase (GPx) mRNA expression and activity, and kidney triglyceride (TG) concentrations were measured. Histology was evaluated by light microscopy with immunohistochemistry for p53, p53-upregulated modulation of apoptosis (PUMA), and terminal deoxynucleotide transferase dUTP nick end-labeling (TUNEL) staining. CP induced renal tubular damage with a higher MDA level, increased PUMA expression, p53- and TUNEL-positive cells counts, elevation of serum lipids, and decreased GSH level, GPx mRNA expression, and activity. Pravastatin partially ameliorated CP-induced renal injury, based on suppression of the renal MDA and TG levels, decreased p53 expression, and apoptosis in CP-treated rats. These findings suggest that pravastatin has a partial protective effect against CP nephrotoxicity via antioxidant activity as well as attenuation of the p53 response, and lipid-lowering effects.
authors.affiliation: Department of Pediatrics, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan. fujiedam@kochi-u.ac.jp
authors.forename: Mikiya
authors.initials: M
authors.lastname: Fujieda
authors.forename: Taku
authors.initials: T
authors.lastname: Morita
authors.forename: Keishi
authors.initials: K
authors.lastname: Naruse
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Hayashi
authors.forename: Masayuki
authors.initials: M
authors.lastname: Ishihara
authors.forename: Tadafumi
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Tomoko
authors.initials: T
authors.lastname: Toma
authors.forename: Kazuhize
authors.initials: K
authors.lastname: Ohta
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Wakiguchi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D017209:Apoptosis / Q000187:drug effects; D051017:Apoptosis Regulatory Proteins / Q000235:genetics / Q000378:metabolism; D002945:Cisplatin / Q000633:toxicity*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D005978:Glutathione / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000235:genetics / Q000378:metabolism; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D007677:Kidney Function Tests; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D017035:Pravastatin / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism; D015854:Up-Regulation
chemical_list: D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; C533952:Bbc3 protein, rat; D016159:Tumor Suppressor Protein p53; D008315:Malondialdehyde; D005979:Glutathione Peroxidase; D005978:Glutathione; D017035:Pravastatin; D002945:Cisplatin